. Author manuscript; available in PMC: 2016 Jul 1.

Published in final edited form as: Metalloproteinases Med. 2015 Oct 30;2:75–82. doi: 10.2147/MNM.S74093

Table 1.

MMP Interventions that improve post-MI outcomes

Intervention	Model	Time post-MI effect observed	Effect
Broad-spectrum MMP inhibitor	Mouse	4 days	↓ LV dilation, ↑ neovascularization
(CP-471 and CP-474)^23,24	Rabbit	4 weeks
Broad-spectrum MMP inhibitor (PD166793)²⁵	Pig	5 days	↓ MI size and expansion
Broad-spectrum MMP inhibitor (PGE-530742)²⁶	Pig	10 days	↓ LV end-diastolic volume
Broad-spectrum MMP inhibitor (TISAM)²⁷	Mouse	3 days	↑ Survival, ↓ rupture
MMP-9 null³¹	Mouse	Up to 15 days	↓ LV enlargement, collagen accumulation
Macrophage-specifc MMP-9 Tg³⁰	Mouse	5 days	↑ LV function, ↓ inflammation
Sitaxsentan³³	Rat	3 days	↓ LV dilation
Doxycycline³⁴	Human	24 hours post-MI up to 9 days	↓ Endothelial dysfunction and ↓ MMP-2, MMP-8, MMP-12, TIMP-1, and TMP-2
Angiotensin-converting enzyme inhibitors³⁶	Human	Up to 30 days	↓ MMP-1 levels and collagenolytic activity
TIMP null^40,41,43,44	Mouse	Up to 14 days	↑ LV remodeling

Abbreviations: ↓, decreased; ↑, increased; Lv, left ventricle; MI, myocardial infarction; MMP, matrix metalloproteinase; Tg, transgenic; TIMP, tissue inhibitor of metalloproteinase; TISAM, 2R-2-[5-[4-[ethyl-methylamino]phenyl]thiophene-2-sulfonylamino]-3-methylbutyric acid.